SCHEMBL8093833

SCHEMBL8093833

COc1ccc(S(=O)(=O)NC(CN)C(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.63
SLC1A2 P43004 1/20 0.63
SLC1A1 P43005 1/20 0.63
MMP2 P08253 16/20 0.61
MMP13 P45452 11/20 0.61
MMP9 P14780 9/20 0.61
MMP3 P08254 8/20 0.61
MMP1 P03956 7/20 0.61
MMP8 P22894 3/20 0.59
MMP7 P09237 1/20 0.58
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA12 O43570 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7653482 0.99 SLC1A3 (0.61) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL7444501 0.89 SLC1A3 (0.56) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL7444497 0.89 SLC1A3 (0.56) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL13571156 0.87 MMP2 (0.60) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL13571241 0.87 MMP2 (0.60) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL13570945 0.87 MMP2 (0.60) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL4621504 0.87 MMP2 (0.66) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL4619626 0.87 MMP2 (0.66) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL13570807 0.87 MMP2 (0.62) SLC1A3SLC1A2SLC1A1MMP2MMP13
SCHEMBL13570499 0.87 MMP2 (0.62) SLC1A3SLC1A2SLC1A1MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1051625-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES Du Pont Pharmaceuticals Company (US) 2000-11-15 EP disclosed
WO-1999038014-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-29 WO disclosed